Allogeneic CD34 positive Enriched Peripheral Blood Stem Cells (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2022/11/05 15:18:10

Base Information

Drug NameAllogeneic CD34 positive Enriched Peripheral Blood Stem Cells (Fred Hutchinson Cancer Research Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A